US Pharma MarketingHow one biotech is using
Epicrispr reports early cut data showing lean muscle gains on its FSHD epigenetic editing therapy EPI-321, using AI Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies…
Epicrispr Biotechnologies on Friday shared an early cut of data from its study of an epigenetic editing therapy for a genetic disease that leads to progressive weakening of the skeletal muscles.
The Bay Area biotech’s ...
Source: Endpoints News